This is a preview of subscription content, log in via an institution to check access.
References
Collins, F.S. & Barker, A.D. Sci. Am. 296, 50–57 (2007).
Hudson, T.J. et al. Nature 464, 993–998 (2010).
Gerlinger, M. et al. N. Engl. J. Med. 366, 883–892 (2012).
Andersson, A.K. et al. Nat. Genet. 47, 330–337 (2015).
Keats, J.J. et al. Blood 120, 1067–1076 (2012).
van Thuijl, H.F. et al. Acta Neuropathol. 129, 597–607 (2015).
Patch, A.M. et al. Nature 521, 489–494 (2015).
Topp, M.D. et al. Mol. Oncol. 8, 656–668 (2014).
Quintana, E. et al. Cancer Cell 18, 510–523 (2010).
Read, M. et al. Ann. Surg. Oncol. 23, 305–311 (2016).
Lawrence, M.G. et al. Nat. Protoc. 8, 836–848 (2013).
Laidlaw, I.J. et al. Endocrinology 136, 164–171 (1995).
van der Linden, A. et al. PLoS One 9, e115675 (2014).
Pentz, R.D. et al. Nat. Med. 11, 1145–1149 (2005).
Lindell, K.O., Erlen, J.A. & Kaminski, N. PLoS Med. 3, e234 (2006).
Steinhauser, K.E. et al. Ann. Intern. Med. 132, 825–832 (2000).
Dedova, I. et al. Int. J. Mol. Sci. 10, 366–384 (2009).
Gundem, G. et al. Nature 520, 353–357 (2015).
Campbell, P.J. et al. Nature 467, 1109–1113 (2010).
Shah, S.P. et al. Nature 461, 809–813 (2009).
Krøigård, A.B. et al. Oncotarget 6, 5634–5649 (2015).
Cassidy, J.W., Caldas, C. & Bruna, A. Cancer Res. 75, 2963–2968 (2015).
Eirew, P. et al. Nature 518, 422–426 (2015).
Hulette, C.M. J. Neuropathol. Exp. Neurol. 62, 715–722 (2003).
Kretzschmar, H. Nat. Rev. Neurosci. 10, 70–78 (2009).
Embuscado, E.E. et al. Cancer Biol. Ther. 4, 548–554 (2005).
Rubin, M.A. et al. Clin. Cancer Res. 6, 1038–1045 (2000).
Beach, T.G. et al. Neuropathology 35, 354–389 (2015).
Carithers, L.J. et al. Biopreserv. Biobank. 13, 311–319 (2015).
Acknowledgements
The CASCADE program was funded initially by a grant from the Peter MacCallum Cancer Foundation. The CASCADE investigators would like to acknowledge the support and guidance of the CASCADE Management Committee. kConFab wishes to thank E. Niedermayr, all the kConFab research nurses and staff, the heads and staff of Family Cancer Clinics and the Clinical Follow Up Study (which has received funding from the NHMRC, the National Breast Cancer Foundation, Cancer Australia and the US National Institutes of Health) for contributions to this resource, and the many families who contribute to kConFab. We sincerely thank the hospital and hospice staff involved in the care of CASCADE participants, the staff at Tobin Brothers Funerals, the Victorian Institute of Forensic Medicine and the participants and their family members. This work was supported by the Peter MacCallum Cancer Foundation; the National Health and Medical Research Council (APP631701 and APP1092856 to D.B., APP1035721 to M.G.L; APP1002648 to G.P.R., APP1035298 to C.F., APP628735 to M.S., APP1054618 to A.P, and APP1062702 to C.S.) to Ovarian Cancer Australia to D.B., the Victorian Cancer Agency (EOI09_27 and CRF13026 (clinical research fellowship to L.M.)); the National Breast Cancer Foundation of Australia (14-067, Infrastructure Grant (kConFab)); the Cancer of the Prostate Translational Research in Victoria (CAPTIV) Collaboration; Amgen (S.S.); the Peter and Lyndy White Foundation; the ANZ Trustees; the Queensland Cancer Fund; the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia; the Cancer Foundation of Western Australia; Prostate Cancer Foundation of Australia (Movember Young Investigator grant to M.G.L.); Pfizer Australia; the Victorian Endowment for Science, Knowledge and Innovation (M.S.); the Lorenzo and Pamela Galli Charitable Trust; the Cancer Council Victoria Sir Edward Dunlop Fellowship in Cancer Research (CS); CRC for Cancer Therapeutics (M.T.) and the Stafford Fox Medical Research Foundation. Work performed by C.S. was made possible through Victorian State Government Operational Infrastructure Support, Australian Government NHMRC IRIISS and the Australian Cancer Research Foundation.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Methods, Supplementary Figures 1–3, and Supplementary Table 1 (PDF 1160 kb)
Rights and permissions
About this article
Cite this article
Alsop, K., Thorne, H., Sandhu, S. et al. A community-based model of rapid autopsy in end-stage cancer patients. Nat Biotechnol 34, 1010–1014 (2016). https://doi.org/10.1038/nbt.3674
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3674
- Springer Nature America, Inc.
This article is cited by
-
Ethical and practical considerations for HIV cure-related research at the end-of-life: a qualitative interview and focus group study in the United States
BMC Medical Ethics (2022)
-
Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling
Nature Communications (2021)
-
Cancer biology as revealed by the research autopsy
Nature Reviews Cancer (2019)
-
Ethical considerations for HIV cure-related research at the end of life
BMC Medical Ethics (2018)